Skip to Content

Lumigan Side Effects

Generic Name: bimatoprost ophthalmic

Note: This page contains information about the side effects of bimatoprost ophthalmic. Some of the dosage forms included on this document may not apply to the brand name Lumigan.

Not all side effects for Lumigan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to bimatoprost ophthalmic: ophthalmic solution

In addition to its needed effects, some unwanted effects may be caused by bimatoprost ophthalmic (the active ingredient contained in Lumigan). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking bimatoprost ophthalmic:

Less common
  • Blindness
  • bloody eye
  • blurred or decreased vision
  • change in color vision
  • color changes in the skin around the eyes
  • difficulty seeing at night
  • disturbed color perception
  • double vision
  • dry eyes
  • eye color changes
  • fever or chills
  • halos around lights
  • lack or loss of strength
  • loss of vision
  • night blindness
  • overbright appearance of lights
  • redness, burning, dry, or itching eyes
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • tunnel vision

Some of the side effects that can occur with bimatoprost ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Body aches or pain
  • cough
  • difficulty with breathing
  • ear congestion
  • headache
  • loss of voice
  • nasal congestion
  • redness of the white part of eyes or inside of the eyelids
  • runny nose
  • sneezing
  • sore throat
  • unusual tiredness or weakness
Less common
  • Darkening of the eyelashes
  • eye discharge or excessive tearing
  • eye strain
  • feeling of having something in the eye
  • increase in hair growth
  • increased sensitivity of the eyes to sunlight

For Healthcare Professionals

Applies to bimatoprost ophthalmic: ophthalmic solution


Bimatoprost can increase the amount of brown pigment in the eye by stimulating melanin production in melanocytes. The change in eye color occurs gradually over months to years and may be permanent. The entire or parts of the iris may be affected. Changes may be more prominent in patients with green-brown, blue/gray-brown or yellow-brown irides.

The manufacturer reports approximately 3% of patients discontinue therapy due to conjunctival hyperemia.

One study (n=133) reported trace or mild conjunctival hyperemia in up to 55.4% of patients with a mean grade of 0.55 on a scale of 0 to 3. Also reported were eyelash growth (10.5%), ocular pruritus (9.8%), and ocular burning (5.3%).[Ref]

Ocular side effects have been reported the most frequently. Ocular side effects reported in 15% to 45% of patients have included conjunctival hyperemia, growth of eyelashes, and ocular pruritus. Ocular dryness, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening have been reported in 3% to 10% of patients. Eye discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, increased iris pigmentation, and conjunctival edema have been reported in 1% to 3% of patients. Intraocular inflammation or iritis has been reported rarely (less than 1%). Macular edema, including cystoid macular edema, has also been reported. Postmarketing reports have included eyelid edema and periorbital and lid changes associated with a deepening of the eyelid sulcus.[Ref]


A 59-year-old Hispanic woman developed hypertrichosis of vellus hairs on the left malar region within 4 weeks of initiating unilateral therapy (left eye). Therapy was discontinued and the condition did not recur following epilation.

Two cases of poliosis were reported in as early as six weeks of treatment. Affected lashes were interspersed with normally pigmented lashes. Hypertrichosis was also reported in these patients.[Ref]

Dermatologic side effects have included increases in length, thickness, pigmentation, and/or number of eyelashes. These changes may be permanent. Bimatoprost may also cause increased brown pigmentation of the eyelashes, periorbital and/or eyelid tissue of the treated eye. Hirsutism has been reported in less than 5% of patients. There is a single case report of hypertrichosis of vellus hairs in the malar region.[Ref]


Respiratory side effects have included colds and upper respiratory tract infections in approximately 10% of patients.[Ref]

Nervous system

Nervous system side effects have included headache (less than 5%). Postmarketing reports have included dizziness.[Ref]


Hepatic system side effects have included abnormal liver function tests (<5%).[Ref]


Other side effects have included asthenia (<5%).[Ref]


Cardiovascular side effects have included hypertension.


Gastrointestinal side effects have included nausea.


1. Herndon LW, Robert D Williams, Wand M, Asrani S "Increased periocular pigmentation with ocular hypotensive lipid use in African Americans." Am J Ophthalmol 135 (2003): 713-5

2. Wand M, Shields BM "Cystoid macular edema in the era of ocular hypotensive lipids." Am J Ophthalmol 133 (2002): 393-7

3. Mushtaq B, Sardar J, Matthews TD "A paradoxical ocular effect of brimonidine." Am J Ophthalmol 135 (2003): 102-3

4. Wand M, Gaudio AR "Cystoid macular edema associated with ocular hypotensive lipids." Am J Ophthalmol 133 (2002): 403-5

5. Tosti A, Pazzaglia M, Voudouris S, Tosti G "Hypertrichosis of the eyelashes caused by bimatoprost." J Am Acad Dermatol 51(5 Suppl) (2004): S149-50

6. Leal BC, Medeiros FA, Medeiros FW, Santo RM, Susanna R Jr "Conjunctival hyperemia associated with bimatoprost use: A histopathologic study." Am J Ophthalmol 138 (2004): 310-3

7. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.

8. Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL "Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost." Am J Ophthalmol 135 (2003): 314-20

9. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM "A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma." Am J Ophthalmol 135 (2003): 55-63

10. "Two new ophthalmic solutions enter glaucoma market." Am J Health Syst Pharm 58 (2001): 1080, 1086

11. Chen CS, Wells J, Craig JE "Topical prostaglandin F(2alpha) analog induced poliosis." Am J Ophthalmol 137 (2004): 965-6

12. Hart J, Shafranov G "Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost." Am J Ophthalmol 137 (2004): 756-7

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.